Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: Role of CB1 receptors

Neurogastroenterology and Motility

Volumn 23, Issue 5, 2011, Pages

  Abalo, R ^a   Cabezos, P A ^a   Vera, G ^a   Lopez miranda V ^a   Herradon E ^a   Martin fontelles M I ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Cannabinoid; Gastrointestinal motility; Hypersensitization; Intermittent administration; Radiology

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH EMPTYING;

ANALGESICS; ANIMALS; BENZOXAZINES; CANNABINOIDS; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; MALE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 79954416029     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01677.x     Document Type: Article

References (38)

1. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009; 60: 77-84.
2. Compton DR, Rice KC, De Costa BR et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993; 265: 218-26.
3. Fox A, Kesingland A, Gentry C et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92: 91-100.
4. García MC, Adler-Graschinsky E, Celuch SM. Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 270-6.
5. Li J, Kaminski NE, Wang DH. Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 2003; 41: 757-62.
6. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008; 52: 601-7.
7. Abalo R, Cabezos PA, Vera G, Fernández-Pujol R, Martín MI. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55, 212-2 on gastrointestinal motility in the rat. Neurogastroenterol Motil 2010; 22: 694-e206.
8. Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001; 1: 597-603.
9. Coruzzi G, Adami M, Guaita E et al. Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig Dis Sci 2006; 51: 310-7.
10. Germanò MP, D'Angelo V, Mondello MR et al. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn Schmiedebergs Arch Pharmacol 2001; 363: 241-4.
11. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126: 21-38.
12. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-67.
13. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004; 141: 1335-45.
14. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. Handb Exp Pharmacol 2005; 168: 573-98.
15. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005; 83: 944-54.
16. Fioramonti J, Bueno L. Role of cannabinoid receptors in the control of gastrointestinal motility and perception. Expert Rev Gastroenterol Hepatol 2008; 2: 385-97.
17. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999; 384: 37-42.
18. Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Manara L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur J Pharmacol 2002; 450: 77-83.
19. Abalo R, Cabezos PA, López-Miranda V et al. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55, 212-2 in the rat. Neurogastroenterol Motil 2009; 21: 1002-e80.
20. Compton WM, Grant BF, Colliver JD et al. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004; 291: 2114-21.
21. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55, 212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007; 81: 468-79.
22. Martin MI, Vera G, Chiarlone A, Cabezos PA, Abalo R. The cannabinoid agonist WIN 55, 212-2 prevents the development of mechanical allodynia induced by chronic cisplatin in the rat. Eur J Pain 2006; 10: S58.
23. De Lago E, Ligresti A, Ortar G et al. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol 2004; 484: 249-57.
24. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55, 212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005; 118: 23-34.
25. Cabezos PA, Vera G, Castillo M, Fernández-Pujol R, Martín MI, Abalo R. Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci 2008; 141: 54-65.
26. Pascual D, Girón R, Alsasua A, Benhamú B, López-Rodríguez ML, Martín MI. New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists. Eur J Pharmacol 2003; 462: 99-107.
27. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 1992; 105: 980-4.
28. Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
29. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319: R3-4.
30. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999; 96: 12198-12203.
31. Pinto L, Izzo AA, Cascio MG et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 227-34.
32. Di Marzo V, Capasso R, Matias I et al. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 2008; 153: 1272-80.
33. Storr MA, Bashashati M, Hirota C et al. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil 2010; 22: 787-96.
34. Carai MA, Colombo G, Gessa GL. Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant). Eur J Pharmacol 2004; 494: 221-4.
35. Makwana R, Molleman A, Parsons ME. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol 2010; 160: 615-26.
36. Boesmans W, Ameloot K, van den Abbeel V, Tack J, Vanden Berghe P. Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol Motil 2009; 21: 958-e77.
37. Limebeer CL, Vemuri VK, Bedard H et al. Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 2010; 161: 336-49.
38. Cluny NL, Vemuri VK, Chambers AP et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010; 161: 629-42.